|
|
|
Insider
Information: |
Baker Bros. Advisors (gp) Llc |
Relationship: |
|
City: |
New York |
State: |
NY |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
16 |
|
Direct
Shares |
608,718 |
|
Indirect Shares
|
158,658,441 |
|
|
Direct
Value |
$42,508,355 |
|
|
Indirect Value
|
$12,755,792,609 |
|
|
Total
Shares |
159,267,159 |
|
|
Total
Value |
$12,798,300,963 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
1
|
Stock
price went up :
|
0
|
0
|
Stock
price went down : |
0
|
1
|
|
|
|
Gain/Loss Ratio : |
0.0
|
-1.0
|
Percentage
Gain/Loss : |
0.0%
|
-74.7%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Genomic Health Inc |
GHDX |
Director, 10% Owner |
2013-07-01 |
0 |
2019-02-27 |
9,235,362 |
Premium* |
|
Acadia Pharmaceuticals Inc |
ACAD |
Director, 10% Owner |
2014-03-05 |
0 |
2016-04-01 |
41,897,946 |
Premium* |
|
Incyte Corp |
INCY |
Director, 10% Owner |
2021-05-14 |
559,963 |
2021-05-14 |
29,367,926 |
Premium* |
|
XOMA Corporation |
XOMA |
Director, 10% Owner |
2014-05-22 |
0 |
2014-05-22 |
518,849 |
Premium* |
|
Aceragen, Inc |
ACGN |
Director |
2014-07-01 |
0 |
2016-01-04 |
78,885 |
Premium* |
|
Synageva BioPharma Corp |
GEVA |
Director, 10% Owner |
2015-01-07 |
1,020 |
2015-01-07 |
11,877,394 |
Premium* |
|
Mirati Therapeutics, Inc. |
MRTX |
10% Owner |
2016-06-09 |
274 |
2016-06-09 |
30,003 |
Premium* |
|
Intellia Therapeutics, Inc. |
NTLA |
Former 10% owner |
2016-05-11 |
0 |
2016-05-11 |
976,214 |
Premium* |
|
Invitae Corp |
NVTA |
10% Owner |
2016-11-17 |
0 |
2016-11-17 |
6,554,039 |
Premium* |
|
Bellicum Pharmaceuticals, Inc |
BLCM |
10% Owner |
2017-03-24 |
0 |
2023-11-22 |
2,168,818 |
Premium* |
|
Seagen Inc |
SGEN |
Director, 10% Owner |
2023-05-31 |
46,557 |
2023-05-31 |
42,977,301 |
Premium* |
|
Neurogene |
NGNE |
Director, 10% Owner |
2023-10-05 |
904 |
2023-10-05 |
1,658,190 |
Premium* |
|
Entrada Therapeutics, Inc. |
TRDA |
10% Owner |
2022-05-16 |
0 |
2022-06-06 |
4,501,658 |
Premium* |
|
Atreca Inc |
BCEL |
Former 10% Owner |
2023-10-19 |
0 |
2023-10-19 |
2,971,128 |
Premium* |
|
Igm Biosciences, Inc. |
IGMS |
|
2023-12-13 |
0 |
2024-03-29 |
3,755,474 |
Premium* |
|
Vtv Therapeutics Inc. |
VTVT |
|
2024-03-05 |
0 |
2024-03-05 |
89,254 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
103 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 1 of 5
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
GHDX |
Genomic Health Inc |
Director |
|
2013-07-01 |
4 |
A |
$32.85 |
$119,443 |
I/I |
3,636 |
301,821 |
0 |
- |
|
GHDX |
Genomic Health Inc |
Director |
|
2013-10-01 |
4 |
A |
$30.33 |
$119,743 |
I/I |
3,948 |
302,479 |
0 |
- |
|
GHDX |
Genomic Health Inc |
Director |
|
2014-01-01 |
4 |
A |
$29.27 |
$119,773 |
I/I |
4,092 |
303,161 |
0 |
- |
|
ACAD |
Acadia Pharmaceuticals In... |
Director |
|
2014-03-05 |
4 |
B |
$28.50 |
$15,000,006 |
I/I |
526,316 |
452,540 |
2.25 |
- |
|
GHDX |
Genomic Health Inc |
Director |
|
2014-04-01 |
4 |
A |
$26.57 |
$119,884 |
I/I |
4,512 |
303,913 |
0 |
- |
|
INCY |
Incyte Corp |
Director |
|
2014-05-21 |
4 |
OE |
$7.02 |
$210,600 |
I/I |
30,000 |
390,839 |
0 |
- |
|
XOMA |
XOMA Corporation |
Director |
|
2014-05-22 |
4 |
A |
$0.00 |
$0 |
I/I |
25,200 |
518,849 |
0 |
- |
|
GHDX |
Genomic Health Inc |
Director |
|
2014-07-01 |
4 |
A |
$27.86 |
$119,687 |
I/I |
4,296 |
304,629 |
0 |
- |
|
ACGN |
Aceragen, Inc |
Director |
|
2014-07-01 |
4 |
A |
$2.83 |
$52,485 |
I/I |
18,546 |
41,287 |
0 |
- |
|
ACGN |
Aceragen, Inc |
Director |
|
2014-10-01 |
4 |
A |
$2.16 |
$57,763 |
I/I |
26,742 |
50,201 |
0 |
- |
|
GHDX |
Genomic Health Inc |
Director |
|
2014-10-01 |
4 |
A |
$28.54 |
$119,868 |
I/I |
4,200 |
305,329 |
0 |
- |
|
GHDX |
Genomic Health Inc |
Director |
|
2015-01-01 |
4 |
A |
$31.97 |
$119,696 |
I/I |
3,744 |
305,953 |
0 |
- |
|
ACGN |
Aceragen, Inc |
Director |
|
2015-01-02 |
4 |
A |
$4.90 |
$57,727 |
I/I |
11,781 |
54,128 |
0 |
- |
|
GEVA |
Synageva BioPharma Corp |
Director |
|
2015-01-07 |
4 |
B |
$94.19 |
$94,190,000 |
I/I |
1,000,000 |
9,184,771 |
2.25 |
- |
|
ACGN |
Aceragen, Inc |
Director |
|
2015-02-13 |
4 |
B |
$3.75 |
$19,999,999 |
I/I |
5,333,333 |
6,323,855 |
2.1 |
- |
|
GHDX |
Genomic Health Inc |
Director |
|
2015-04-01 |
4 |
A |
$30.43 |
$119,772 |
I/I |
3,936 |
306,609 |
0 |
- |
|
ACGN |
Aceragen, Inc |
Director |
|
2015-04-01 |
4 |
A |
$3.52 |
$57,763 |
I/I |
16,410 |
59,598 |
0 |
- |
|
INCY |
Incyte Corp |
Director |
|
2015-05-11 |
4 |
OE |
$7.68 |
$460,800 |
I/I |
60,000 |
410,839 |
0 |
- |
|
INCY |
Incyte Corp |
Director |
|
2015-07-01 |
4 |
A |
$104.21 |
$56,899 |
I/I |
546 |
411,021 |
0 |
- |
|
ACGN |
Aceragen, Inc |
Director |
|
2015-07-01 |
4 |
A |
$3.66 |
$57,755 |
I/I |
15,780 |
64,858 |
0 |
- |
|
GHDX |
Genomic Health Inc |
Director |
|
2015-07-01 |
4 |
A |
$27.34 |
$119,749 |
I/I |
4,380 |
307,339 |
0 |
- |
|
MRTX |
Mirati Therapeutics, Inc. |
10% Owner |
|
2015-09-16 |
4 |
B |
$45.00 |
$6,750,000 |
I/I |
150,000 |
2,744,052 |
1.5 |
- |
|
INCY |
Incyte Corp |
Director |
|
2015-09-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
14,698 |
61,049 |
0 |
- |
|
INCY |
Incyte Corp |
Director |
|
2015-09-16 |
4 |
OE |
$0.00 |
$0 |
I/I |
4,609,228 |
512,673 |
0 |
- |
|
INCY |
Incyte Corp |
Director |
|
2015-10-01 |
4 |
A |
$110.33 |
$56,930 |
I/I |
516 |
512,845 |
0 |
- |
|
103 Records found
|
|
Page 1 of 5 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|